TY - JOUR
T1 - Carrier-mediated transport of the quaternary ammonium neuronal nicotinic receptor antagonist N,N′-dodecylbispicolinium dibromide at the blood-brain barrier
AU - Lockman, Paul R.
AU - Manda, Vamshi K.
AU - Geldenhuys, Werner J.
AU - Mittapalli, Rajendar K.
AU - Thomas, Fancy
AU - Albayati, Zaineb Fadhel
AU - Crooks, Peter A.
AU - Dwoskin, Linda P.
AU - Allen, David D.
N1 - Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2008/1
Y1 - 2008/1
N2 - The quaternary ammonium compound N,N′-dodecyl-bispicolinium dibromide (bPiDDB) potently and selectively inhibits nicotinic receptors (nAChRs) mediating nicotine-evoked [3H]dopamine release and decreases nicotine self-administration, suggesting that this polar, charged molecule penetrates the blood-brain barrier (BBB). This report focuses on 1) BBB penetration of bPiDDB; 2) the mechanism of permeation; and 3) comparison of bPiDDB to the cations choline and N-octylnicotinium iodide (NONI), both of which are polar, charged molecules that undergo facilitated BBB transport. The BBB permeation of [3H]choline, [3H]NONI, and [14C]bPiDDB was evaluated using in situ rat brain perfusion methods. Cerebrovascular permeability surface-area product (PS) values for [3H]choline, [ 3H]NONI, and [14C]bPiDDB were comparable (1.33 ± 0.1, 1.64 ± 0.15, and 1.3 ± 0.3 ml/s/g, respectively). To ascertain whether penetration was saturable, unlabeled substrate was added to the perfusion fluid. Unlabeled choline (500 μM) reduced the PS of [ 3H]choline to 0.15 ± 0.06 μl/s/g (p < 0.01). Likewise, unlabeled bPiDDB (500 μM) reduced the PS of [14C]bPiDDB to 0.046 ± 0.005 μl/s/g (p < 0.01), whereas unlabeled NONI reduced the PS for [3H]NONI by approximately 50% to 0.73 ± 0.31 μl/s/g. The PS of [14C]bPiDDB was reduced (p < 0.05) in the presence of 500 μM choline, indicating that the BBB choline transporter may be responsible for the transport of bPiDDB into brain. Saturable kinetic parameters for [14C]bPiDDB were similar to those for [3H]choline. The current results suggest that bPiDDB uses the BBB choline transporter for ∼90% of its permeation into brain, and they demonstrate the carrier-mediated BBB penetration of a novel bisquaternary ammonium nAChR antagonist.
AB - The quaternary ammonium compound N,N′-dodecyl-bispicolinium dibromide (bPiDDB) potently and selectively inhibits nicotinic receptors (nAChRs) mediating nicotine-evoked [3H]dopamine release and decreases nicotine self-administration, suggesting that this polar, charged molecule penetrates the blood-brain barrier (BBB). This report focuses on 1) BBB penetration of bPiDDB; 2) the mechanism of permeation; and 3) comparison of bPiDDB to the cations choline and N-octylnicotinium iodide (NONI), both of which are polar, charged molecules that undergo facilitated BBB transport. The BBB permeation of [3H]choline, [3H]NONI, and [14C]bPiDDB was evaluated using in situ rat brain perfusion methods. Cerebrovascular permeability surface-area product (PS) values for [3H]choline, [ 3H]NONI, and [14C]bPiDDB were comparable (1.33 ± 0.1, 1.64 ± 0.15, and 1.3 ± 0.3 ml/s/g, respectively). To ascertain whether penetration was saturable, unlabeled substrate was added to the perfusion fluid. Unlabeled choline (500 μM) reduced the PS of [ 3H]choline to 0.15 ± 0.06 μl/s/g (p < 0.01). Likewise, unlabeled bPiDDB (500 μM) reduced the PS of [14C]bPiDDB to 0.046 ± 0.005 μl/s/g (p < 0.01), whereas unlabeled NONI reduced the PS for [3H]NONI by approximately 50% to 0.73 ± 0.31 μl/s/g. The PS of [14C]bPiDDB was reduced (p < 0.05) in the presence of 500 μM choline, indicating that the BBB choline transporter may be responsible for the transport of bPiDDB into brain. Saturable kinetic parameters for [14C]bPiDDB were similar to those for [3H]choline. The current results suggest that bPiDDB uses the BBB choline transporter for ∼90% of its permeation into brain, and they demonstrate the carrier-mediated BBB penetration of a novel bisquaternary ammonium nAChR antagonist.
UR - http://www.scopus.com/inward/record.url?scp=37349073219&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37349073219&partnerID=8YFLogxK
U2 - 10.1124/jpet.107.130906
DO - 10.1124/jpet.107.130906
M3 - Article
C2 - 17921191
AN - SCOPUS:37349073219
SN - 0022-3565
VL - 324
SP - 244
EP - 250
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 1
ER -